UCLA Health and UC San Francisco scientists have identified a natural protein complex that helps certain brain cells destroy toxic tau before it can clump and kill neurons, offering potential targets for Alzheimer’s treatments.
The study, published in Cell, used a large-scale CRISPR-based genetic screening technique on lab-grown human neurons to map which genes control tau accumulation. According to the research, a protein complex called CRL5SOCS4 tags tau with molecular markers that direct it to the cell’s waste disposal system for breakdown — effectively acting as a cleanup mechanism that some neurons possess at higher levels than others.
When researchers examined brain tissue from Alzheimer’s patients, neurons with higher concentrations of CRL5SOCS4 components were more likely to have survived despite tau accumulation, the study says.
Screening Nearly Every Gene in the Human Genome
“We wanted to understand why some neurons are vulnerable to tau accumulation while others are more resilient,” said Dr. Avi Samelson, the study’s first author and assistant professor of Neurology at UCLA Health, who conducted the research while at UCSF. “By systematically screening nearly every gene in the human genome, we found both expected pathways and completely unexpected ones that control tau levels in neurons.”
Using a gene-silencing tool called CRISPRi, the team switched off individual genes across more than 1,000 flagged candidates in human stem cell-derived neurons to observe the effect on toxic tau clumping. CRL5SOCS4 emerged as a standout: when its activity is sufficient, tau gets chemically marked and routed to the cell’s recycling machinery for destruction.
Tau is the most common protein known to aggregate in neurodegenerative disorders, contributing to conditions including Alzheimer’s disease and frontotemporal dementia. Why some neurons resist that buildup while others collapse has remained poorly understood.
Mitochondrial Stress Produces a Dangerous Tau Fragment
The research also identified an unexpected connection between mitochondrial dysfunction and tau toxicity. When the team disrupted the cell’s energy-generating structures in experiments, the neurons began producing a specific tau fragment measuring approximately 25 kilodaltons — closely matching a biomarker called NTA-tau already detected in the blood and spinal fluid of Alzheimer’s patients.
“This tau fragment appears to be generated when cells experience oxidative stress, which is common in aging and neurodegeneration,” Samelson said. “We found that this stress reduces the efficiency of the proteasome, the cell’s protein recycling machine, causing it to improperly process tau.”
Laboratory experiments showed the altered fragment changes how tau proteins cluster, which the study suggests may influence disease progression.
The announcement says boosting CRL5SOCS4 activity could form the basis of new therapies for neurodegenerative diseases — conditions that affect millions and still lack effective treatments. Identifying how mitochondrial stress generates the NTA-tau fragment adds a second potential intervention point: disrupting that production pathway before the fragment forms.
The research was conducted using human neurons grown in a lab setting, meaning further studies in more complex biological systems will be needed before any clinical applications can be assessed.
Photo by Fayette Reynolds M.S. on Pexels
This article is a curated summary based on third-party sources. Source: Read the original article
